SS 31 peptide - with longer term treatment, does the repair effected on mitochondria last after treatment is stopped

Most of the available data suggest that SS-31 (elamipretide) improves mitochondrial function while it is being given, and some of the functional benefits can persist for a period after you stop, but the effect is only partially durable and tends to wane over weeks to months.[1] [2] [3]

What has been seen after stopping SS-31?

- In aged mice treated for 8 weeks, improvements in diastolic cardiac function were still present 2 weeks after stopping SS-31, but had fallen to about half of their on-treatment size by 4 weeks, indicating a **partial** persistence of benefit with gradual loss over time.[1]
- A review of SS-31 in aged hearts notes that roughly half of the functional effect remained 4 weeks after discontinuation, again implying that the benefit is not fully permanent without ongoing therapy.[2]
- In a mouse model of age-related visual decline treated with a related mitochondria-targeting peptide, recovered visual function persisted for at least 3 months after treatment withdrawal, suggesting that some downstream tissue remodeling can maintain benefit beyond the drug's presence.[3]

What this likely means for "mitochondrial repair"

- SS-31 stabilizes cardiolipin, reduces mitochondrial reactive oxygen species, improves membrane potential, and decreases proton leak; these actions restore more normal energetics and redox balance while the drug is present.[4] [5] [1]
- Some of the "repair" appears to involve downstream structural and signaling changes (for example, improved muscle or cardiac remodeling), which can maintain **partial** functional gains after stopping.[6] [2] [1]
- However, studies that followed animals after washout consistently show that benefits decline over time once treatment stops, and the duration and magnitude of persistence vary by tissue and individual.[2] [3] [1]

Human data

- Long-term elamipretide use in conditions like Barth syndrome shows sustained improvements in functional and cardiac measures while therapy continues, but trials have not yet clearly demonstrated robust, permanent correction of mitochondrial defects after discontinuation.[7] [8]
- Current human studies are primarily designed around chronic or long-term administration, reflecting the assumption that ongoing dosing is needed to maintain full benefit.[8] [7]

Practical takeaway

Based on current evidence, SS-31 can reverse aspects of mitochondrial dysfunction and produce tissue-level improvements, and a portion of this benefit may persist for weeks (and in some models months) after you stop, but it does not look permanently curative in most settings studied so far.[3] [4] [1] [2]

⁂

Do new mitochondria produced during the treatment process function better than the damaged mitochondria.

Evidence suggests that during SS-31 treatment, newly generated or remodeled mitochondria tend to function more normally and with higher "quality" than the previously damaged pool, but this reflects both repair of existing mitochondria and improved turnover rather than a simple swap to entirely new organelles.[16] [17] [18] [19]

What SS-31 does to mitochondrial "quality"

- SS-31 binds cardiolipin and stabilizes inner mitochondrial membranes, which improves membrane potential, ATP production, and reduces reactive oxygen species in previously dysfunctional mitochondria.[20] [21]
- In aged skeletal muscle, SS-31 increased ATP production and improved coupling efficiency (P/O ratio) without increasing mitochondrial content, indicating better function per mitochondrion rather than just more mitochondria.[16]
- In several disease models, treated cells show more normal-looking mitochondria on electron microscopy (less swelling, preserved cristae), consistent with a shift toward healthier, more efficient organelles.[22] [23]

Biogenesis, dynamics, and selective removal

- SS-31 can upregulate mitochondrial biogenesis regulators (PGC-1α, NRF1, NRF2, TFAM), which promotes generation of new mitochondria with improved respiratory capacity compared with the damaged baseline.[18] [19]

- It also improves mitochondrial dynamics (more fusion, less pathological fission) and enhances mitophagy, meaning damaged mitochondria are more efficiently removed while healthier ones are preserved or newly formed.[17] [19]
- In beta cells and neurons, elamipretide prevented fragmentation and restored normal morphology, supporting the idea that the post-treatment mitochondrial population is functionally superior to the pre-treatment, damaged pool.[19] [17]

Putting it together

During SS-31 therapy, the combined effects—stabilizing membranes, enhancing biogenesis programs, normalizing fusion–fission, and promoting mitophagy—shift the mitochondrial population toward better-functioning organelles with higher ATP output and lower oxidative stress than the damaged mitochondria present before treatment.[21] [17] [18] [16]

⁂

what is the production level of new mitochondria, related to turnover rate

Mitochondrial “production” (biogenesis) is normally matched to removal (mitophagy), and in many tissues only a few percent of the mitochondrial pool is renewed per day, with big variation by organ and condition.[31] [32] [33]

Baseline turnover and production

- In heart, modeling from mitophagy markers suggests that about 3–4% of mitochondrial mass is replaced each day under resting conditions, implying continuous low-level production of new mitochondria.[31]
- One analysis of cardiac mitochondrial protein turnover estimates an average mitochondrial protein half-life around 17 days at steady state, meaning roughly half the mitochondrial protein pool is renewed over that period.[33]
- In human skeletal muscle, mitochondrial proteins generally have higher synthesis (turnover) rates than bulk mixed proteins, consistent with relatively active ongoing renewal to maintain oxidative capacity.[34]

Tissue and age differences

- mtDNA half-life can range from about 9–11 days in rapidly renewing tissues like liver and adrenal, up to several months in skeletal muscle, indicating that the “clock speed” of turnover is very tissue-specific.[35]
- Within a given tissue, individual mitochondrial proteins can have half-lives from hours to months, so parts of the organelle are being replaced at different rates even when overall mitochondrial number looks stable.[36] [35]

How this relates to “production level”

- In healthy steady state, production (biogenesis) and degradation (mitophagy) are tightly coupled so that mitochondrial number stays roughly constant even though a few percent of the pool is renewed each day.[32] [37] [38]
- Stimuli like endurance exercise, caloric restriction, hypoxia, or pharmacologic agents can temporarily increase biogenesis and/or mitophagy, speeding turnover so damaged mitochondria are removed faster and replaced by better-functioning ones.[39] [40] [33]

So in simple terms, you can think of many tissues as replacing on the order of a few percent of their mitochondria daily at rest, with the turnover rate (and thus production of new mitochondria) increasing when the system is stimulated or stressed.[32] [33] [31]

⁂

How does SS-31 peptide affect mitochondrial turnover rates

SS-31 appears to normalize and modestly **increase** effective mitochondrial turnover by improving mitophagy and quality control, rather than massively ramping up raw mitochondrial production.[47] [48] [49]

Effects on mitophagy (removal side)

- In β-cells exposed to nutrient excess, elamipretide restored the engulfment of mitochondria into autophagosomes, reversing a block in mitophagosome formation and thus improving removal of damaged mitochondria.[48] [47]
- In a Barth syndrome mouse model, SS-31 corrected defective mitophagy along with abnormal mitochondrial morphology, indicating more efficient turnover of dysfunctional organelles.[50]

Effects on biogenesis and “net” turnover

- Reviews and neuronal models report that elamipretide can enhance mitochondrial respiration and support mitochondrial biogenesis programs, helping maintain mitochondrial number despite increased clearance of damaged units.[51] [52]
- In cancer-cachexia models, SS-31 improved mitochondrial efficiency but did not strongly stimulate biogenesis, and could only partially counter excessive mitophagy, suggesting its main action is optimizing quality control rather than driving high-volume replacement.[49]

Overall picture

- SS-31 tends to rebalance the turnover cycle: damaged mitochondria are more effectively tagged and removed, and the remaining/new mitochondria function better, so the “effective” turnover rate of poor-quality mitochondria rises even if total mitochondrial content changes little.[53] [50] [48]

- Quantitatively, current studies do not provide a precise percentage increase in turnover rate, but the consistent finding across cell and animal models is improved mitophagy and quality maintenance, not an extreme acceleration of bulk mitochondrial replacement.[52] [47] [48]

⁂

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC7377906/
2. https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?article=10879&context=open_access_pubs
3. https://journals.biologists.com/dmm/article/15/3/dmm048256/274438/Treatment-of-age-related-visual-impairment-with-a
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC9192202/
5. https://stealthbt.com/wp-content/uploads/Szeto_et_al-2014-Clinical_Pharmacology__Thera.pdf
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC6588449/
7. https://www.sciencedirect.com/science/article/pii/S1098360024000716
8. https://stealthbt.com/wp-content/uploads/MDA_2019_MMPOWER-2_Open-Label_-Extension_Trial.pdf
9. https://www.nmn.com/news/two-molecules-improve-heart-function
10. https://www.fightaging.org/archives/2013/05/mitochondrially-targeted-antioxidant-ss-31-reverses-some-measures-of-aging-in-muscle/
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC11599447/
12. https://peptidesociety.org/_template-monographs-4/
13. https://www.alzdiscovery.org/uploads/cognitive_vitality_media/SS-31-Cognitive-Vitality-For-Researchers.pdf
14. https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2019.00167/full
15. https://www.sciencedirect.com/science/article/pii/S0009279724003120
16. https://pmc.ncbi.nlm.nih.gov/articles/PMC6588449/
17. https://pmc.ncbi.nlm.nih.gov/articles/PMC6290358/
18. https://pmc.ncbi.nlm.nih.gov/articles/PMC6075532/
19. https://www.frontiersin.org/journals/integrative-neuroscience/articles/10.3389/fnint.2021.747901/full
20. https://stealthbt.com/wp-content/uploads/Szeto_et_al-2014-Clinical_Pharmacology__Thera.pdf
21. https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/
22. https://pmc.ncbi.nlm.nih.gov/articles/PMC10240765/
23. https://www.nature.com/articles/s41598-024-64368-y
24. https://www.nature.com/articles/s41598-018-34251-8
25. https://stealthbt.com/wp-content/uploads/Siegel_et_al-2013-Aging_Cell.pdf
26. https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2019.00167/full
27. https://www.sciencedirect.com/science/article/pii/S0009279724003120
28. https://www.rapamycin.news/t/hazel-szeto-ss-31-peptide-the-worlds-first-fda-approved-mitochondria-targeted-drug-longevity-summit-2025/22586/138?tblang=english
29. https://www.sciencedirect.com/science/article/pii/S0753332225002501
30. https://www.sciencedirect.com/science/article/abs/pii/S1567724921000143

31. https://pmc.ncbi.nlm.nih.gov/articles/PMC4333239/
32. https://pmc.ncbi.nlm.nih.gov/articles/PMC4268279/
33. https://pmc.ncbi.nlm.nih.gov/articles/PMC3335292/
34. https://www.pnas.org/doi/10.1073/pnas.93.26.15364
35. https://pmc.ncbi.nlm.nih.gov/articles/PMC11872842/
36. https://www.sciencedirect.com/science/article/pii/S1534580721008091
37. https://pmc.ncbi.nlm.nih.gov/articles/PMC4532782/
38. https://www.nature.com/articles/s41392-023-01503-7
39. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1344075/full
40. https://intsportsnutrition.com/articles/mitochondria-adaptations-to-endurance-training/
41. what-are-the-synergies-between-zNUin5TlRjCz_0izjvNEng.md
42. https://pmc.ncbi.nlm.nih.gov/articles/PMC4746024/
43. https://bionumbers.hms.harvard.edu/bionumber.aspx?id=105606&ver=4
44. https://www.sciencedirect.com/science/article/abs/pii/S0022282814003332
45. https://www.biorxiv.org/content/10.1101/2024.01.21.576451v1.full.pdf
46. https://cdnsciencepub.com/doi/pdf/10.1139/y71-143
47. https://pubmed.ncbi.nlm.nih.gov/30389435/
48. https://pmc.ncbi.nlm.nih.gov/articles/PMC6290358/
49. https://pmc.ncbi.nlm.nih.gov/articles/PMC7923037/
50. https://www.nature.com/articles/s41598-024-64368-y
51. https://www.sciencedirect.com/science/article/pii/S0753332225002501
52. https://www.frontiersin.org/journals/integrative-neuroscience/articles/10.3389/fnint.2021.747901/full
53. https://pmc.ncbi.nlm.nih.gov/articles/PMC6588449/
54. https://pmc.ncbi.nlm.nih.gov/articles/PMC7334473/
55. https://elifesciences.org/articles/55513
56. https://www.sciencedirect.com/science/article/am/pii/S0022283618312348
57. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1680326/full
58. https://www.sciencedirect.com/science/article/pii/S0009279724003120
59. https://onlinelibrary.wiley.com/doi/10.1002/brb3.3508
60. https://www.sciencedirect.com/science/journal/00222836/vsi/10C4RGD8QLK
61. what-are-the-synergies-between-zNUin5TlRjCz_0izjvNEng.md
62. https://www.pnas.org/doi/10.1073/pnas.2002250117